Related Experiment Video
Updated: Feb 8, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Novel Approaches for the Management of AL Amyloidosis
Nisha S Joseph1, Jonathan L Kaufman2
1Winship Cancer Institute, Emory University, 1365C Clifton Road, Atlanta, GA, 30322, USA.
Purpose Of Review:
Light-chain-associated (AL) amyloidosis is a rare disease with a poor prognosis. However, we have made recent strides in more accurate diagnosis and effective treatment. Here, we discuss the most recent updates and advancements during the past year in the diagnosis, prognostication, and management of AL amyloidosis both in the upfront and relapsed setting.
Recent Findings:
New imaging modalities, such as cardiac magnetic resonance (CMR) and use of fluorine-labeled radiotracers, are emerging as an important diagnostic tool in conjunction with biomarkers in the diagnosis, prognosis, and monitoring of the effects of therapy. In addition, ongoing evaluation of plasma cell-directed therapeutics, including daratumumab, pomalidomide, and ixazomib, as well as promising targeted novel therapies, such as the monoclonal antibody NEOD001, are in development. In conclusion, incorporating the use of plasma cell-directed therapy and novel agents targeting the amyloid deposits itself hold enormous potential in achieving improved outcomes in AL amyloidosis.
Related Concept Videos
Frustration and Conflict: Approach-Approach, Approach-Avoidance
One common type of conflict is the Approach–Approach Conflict. In this case, a person faces two desirable...
Tonsillitis II: Management
Impression Management Techniques I: Managing Appearances
Managing Impressions
Management of Insomnia
Cystic Fibrosis: Management
Sinus disease and chronic...

